Pemigatinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Pemigatinib
Accession Number
DB15102
Type
Small Molecule
Groups
Investigational
Description

Pemigatinib is under investigation in clinical trial NCT03656536 (A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)).

Structure
Thumb
Synonyms
  • INCB054828
Categories
Not Available
UNII
Y6BX7BL23K
CAS number
1513857-77-6
Weight
Average: 487.508
Monoisotopic: 487.203110695
Chemical Formula
C24H27F2N5O4
InChI Key
HCDMJFOHIXMBOV-UHFFFAOYSA-N
InChI
InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
IUPAC Name
SMILES
CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
68007304
BindingDB
301310

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentSolid Tumors and Hematologic Malignancy / Tumors, Solid1
1, 2RecruitingTreatmentCancer, Breast / Cholangiocarcinomas / Endometrial Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Malignant Neoplasm of Stomach / Malignant Solid Tumours / MPN / MPN (Myeloproliferative Neoplasms) / Multiple Myeloma (MM) / Myeloproliferative Neoplasms / Neoplasms, Endometrial / NSCLC (Non-small Cell Lung Carcinoma) / Solid Tumors and Hematologic Malignancy / Stomach Neoplasms / Transitional Cell Carcinoma / Tumors, Solid / UC / UC (Urothelial Cancer) / Urothelial Cancer1
2Not Yet RecruitingTreatmentAdvanced or Metastatic Solid Tumors / FGFR Mutations / FGFR Translocations1
2Not Yet RecruitingTreatmentBladder Cancers / NMIBC / Non-muscle Invasive Bladder Cancer (NMIBC) / Urothelial Carcinoma Recurrent1
2Not Yet RecruitingTreatmentUnresectable Urothelial Carcinoma / Urothelial carcinoma ureter metastatic1
2RecruitingTreatmentCholangiocarcinomas1
2RecruitingTreatmentMPN (Myeloproliferative Neoplasms) / Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement1
2RecruitingTreatmentSolid Tumor Malignancies1
2RecruitingTreatmentTransitional Cell Carcinoma / UC (Urothelial Cancer)1
3RecruitingTreatmentMetastatic Cholangiocarcinoma / Unresectable Cholangiocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:50 / Updated on May 21, 2019 12:35